Search

Your search keyword '"Mantzaris, Gerassimos J."' showing total 495 results
Start Over Author "Mantzaris, Gerassimos J."
495 results on '"Mantzaris, Gerassimos J."'

4. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus

Author

Caron, Bénédicte, Abreu, Maria T., Siegel, Corey A., Panaccione, Remo, Sands, Bruce E., Dignass, Axel, Turner, Dan, Dotan, Iris, Hart, Ailsa L., Ahuja, Vineet, Allez, Matthieu, Ananthakrishnan, Ashwin N., Ghosh, Subrata, Griffiths, Anne M., Halfvarson, Jonas, Kaser, Arthur, Kotze, Paulo G., Koutroubakis, Ioannis E., Lakatos, Peter L., Levine, Arie, Lewis, James D., Magro, Fernando, Mantzaris, Gerassimos J., O’Morain, Colm, Ran, Zhihua, Reinisch, Walter, Rogler, Gerhard, Sachar, David B., Siegmund, Britta, Silverberg, Mark S., Sood, Ajit, Spinelli, Antonino, Steinwurz, Flavio, Tysk, Curt, Yamamoto-Furusho, Jesus K., Schreiber, Stefan, Rubin, David T., Sandborn, William J., Danese, Silvio, and Peyrin-Biroulet, Laurent

Published
2022
Full Text
View/download PDF

6. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases

Author

Guillo, Lucas, Abreu, Maria, Panaccione, Remo, Sandborn, William J, Azevedo, Valderilio F, Gensler, Lianne, Moghaddam, Bahar, Ahuja, Vineet, Ali, Sabrina A, Allez, Matthieu, Ananthakrishnan, Ashwin N, Bhattacharya, Abhik, Dubinsky, Marla, Griffiths, Anne, Hart, Ailsa, Korelitz, Burton, Kotze, Paulo G, Koutroubakis, Ioannis E, Lakatos, Peter L, Lindsay, James O, Magro, Fernando, Mantzaris, Gerassimos J, Ng, Siew C, O'Morain, Colm, Panés, Julian, Parigi, Tommaso, Ran, Zhihua, Rogler, Gerhard, Rubin, David T, Sachar, David B, Siegmund, Britta, Steinwurz, Flavio, Tysk, Curt, Vavricka, Stephan, Verstraete, Sofia G, Brezin, Antoine P, Haemel, Anna K, Dignass, Axel, Sands, Bruce E, Danese, Silvio, and Peyrin-Biroulet, Laurent

Published
2022
Full Text
View/download PDF

7. An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.

Author

D'Amico, Ferdinando, Massimino, Luca, Palmieri, Giulia, Dal Buono, Arianna, Gabbiadini, Roberto, Caron, Benedicte, Moreira, Paula, Silva, Isabel, Bosca‐Watts, Maia, Innocenti, Tommaso, Dragoni, Gabriele, Bezzio, Cristina, Zilli, Alessandra, Furfaro, Federica, Saibeni, Simone, Chaparro, María, García, María José, Michalopoulos, George, Viazis, Nikos, and Mantzaris, Gerassimos J.

Subjects
INFLAMMATORY bowel diseases, CROHN'S disease, ULCERATIVE colitis, DISEASE remission, FALSE discovery rate
Abstract

Background and Aims: Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for the treatment of inflammatory bowel diseases (IBDs). Our aim was to evaluate the effectiveness of switching from intravenous (IV) to SC formulations of IFX and VDZ in IBDs. Methods: This multicentre, retrospective study collected data of adult patients with Crohn's disease (CD) or ulcerative colitis (UC) switched to SC IFX or VDZ. The primary endpoint was clinical remission at 12 months stratified based on timing of switch. A composite endpoint consisting of therapy discontinuation, reverse‐switch, need for steroids, and drug optimization was evaluated. A multivariate analysis investigated the association between patients' characteristics and outcomes. Results: Two hundred and thirty‐one patients (59% UC, 53% male, mean age 44 ± 15 years, 68% IFX) from 13 centres were included. The switch occurred at Week 6 in a third of cases (36%). Median time to switch was 13 months. Most patients switched to SC IFX and VDZ were in clinical remission at 3 (87% and 77%), 6 (86% and 83%) and 12 (63% and 60%) months. In the multivariate analysis, there was no difference in clinical remission rate at 12 months; however, patients switched at Week 6 had a higher rate of experiencing any therapeutic changes at 3 (false discovery rate (FDR) =.002), 6 (FDR <1 × 10−10) or 12 months (FDR =.08). Clinical disease activity at baseline (only in UC) (FDR =.07) and previous exposure to biologics (FDR =.001) were risk factors for composite endpoint at 6 and 12 months. Conclusion: SC IFX and VDZ are effective in daily clinical practice in IBD patients. Switching patients in remission reduces the risk of negative outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Outcomes and Endpoints of Postoperative Recurrence in Crohn's Disease: Systematic Review and Consensus Conference.

Author

Hammoudi, Nassim, Sachar, David, D'Haens, Geert, Reinisch, Walter, Kotze, Paulo Gustavo, Vermeire, Severine, Schölmerich, Jürgen, Kamm, Michael A, Griffiths, Anne, Panes, Julian, Ghosh, Subrata, Siegel, Corey A, Bemelman, Willem, O'Morain, Colm, Steinwurz, Flavio, Fleshner, Phillip, Mantzaris, Gerassimos J, Sands, Bruce, Abreu, Maria T, and Dotan, Iris

Abstract

Background Outcomes after ileocolonic resection in Crohn's disease [CD] are heterogeneous, and a clear definition of postoperative recurrence remains to be determined. Our Endpoints Working Group of the International Organization for the study of Inflammatory Bowel Disease [IOIBD] aimed to standardise postoperative outcomes, to discuss which endpoints should be used for postoperative clinical trials, and to define those which could be used in trials or registries. Methods Based on a systematic review of the literature, recommendations and statements were drafted and sent to all IOIBD members for a first round of voting. Recommendations and statements were revised based on the voters' comments during a consensus hybrid conference open to all IOIBD members. If no agreement was reached after two rounds of voting, the statement was excluded. Results In the systematic review, 3071 manuscripts were screened of which 434 were included. Sixteen recommendations were identified, of which 11 were endorsed. Recommendations and statements include that endoscopy remains the gold standard and should be used as a short-term primary endpoint in both observational cohorts and randomised controlled trials. Clinical symptoms classically used in clinical trials for luminal CD are not reliable in this specific situation. For that reason, longer-term endpoints should be based on the evidence of macroscopic inflammation assessed by imaging techniques, endoscopy, or as reflected by the presence of complications. Conclusions Agencies recommend the use of clinical evaluations, as in the case of luminal CD, and do not recognise primary endpoints based solely on endoscopy. This consensus has led to agreement on the need to define postoperative endoscopy-based and/or imaging-based endpoints. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Comparison between tofacitinib and ustekinumab as a third‐line therapy in refractory ulcerative colitis: A multicenter international study

Author

Allocca, Mariangela, Catalano, Gaia, Savarino, Edoardo V., Chaparro, María, Levartovsky, Asaf, Michalopoulos, George, Viazis, Nikos, Fousekis, Fotis S., Psistakis, Andreas, Noviello, Daniele, Nascimento, Catarina Neto do, Caron, Benedicte, Kitsou, Vassiliki, Bamias, Giorgos, García, María José, Zacharopoulou, Eirini, Foteinogiannopoulou, Kalliopi, D'Amico, Ferdinando, Koutroubakis, Ioannis, Ellul, Pierre, Tzouvala, Maria, Peyrin‐Biroulet, Laurent, Torres, Joana, Caprioli, Flavio, Karmiris, Konstantinos, Theodoropoulou, Angeliki, Katsanos, Konstantinos H., Christodoulou, Dimitrios K., Mantzaris, Gerassimos J., Kopylov, Uri, Gisbert, Javier P., Danese, Silvio, Magro, Fernando, Carla, Fornari, and Fiorino, Gionata

Abstract

Ustekinumab and tofacitinib have recently been approved for the management of moderate to severe ulcerative colitis (UC). However, there is no evidence on how they should be positioned in the therapeutic algorithm. The aim of this study was to compare tofacitinib and ustekinumab as third‐line therapies in UC patients in whom anti‐TNF and vedolizumab had failed. This was a multicenter retrospective observational study. The primary outcome was disease progression, defined as the need for steroids, therapy escalation, UC‐related hospitalization and/or surgery. Secondary outcomes were clinical remission, normalization of C‐reactive protein, endoscopic remission, treatment withdrawal, and adverse events. One‐hundred seventeen UC patients were included in the study and followed for a median time of 11.6 months (q1–q3,5.5–18.7). Overall, 65% of patients were treated with tofacitinib and 35% with ustekinumab. In the entire study cohort, 63 patients (54%) had disease progression during the follow‐up period. Treatment with ustekinumab predicted increased risk of disease progression compared to treatment with tofacitinib in Cox regression analysis (HR: 1.93 [95% CI: 1.06–3.50] p= 0.030). Twenty‐eight (68%) patients in the ustekinumab group and 35 (46%) in the tofacitinib group had disease progression over the follow‐up period (log‐rank test, p< 0.054). No significant differences were observed for the secondary outcomes. Six and 22 adverse events occurred in the ustekinumab and tofacitinib groups, respectively (15% vs. 31%, p= 0.11). Tofacitinib was more efficacious in reducing disease progression than ustekinumab in this cohort of refractory UC patients. However, prospective head‐to‐head clinical trials are needed as to confirm these data.

Published
2024
Full Text
View/download PDF

12. Cold snare polypectomy vs. hot snare polypectomy vs. argon plasma coagulation for small (5–9mm) left-sided colorectal polyps: a prospective randomized trial

Author

Varytimiadis, Lazaros, Viazis, Nikos, Gkolfakis, Paraskevas, Tribonias, Georgios, Tziatzios, Georgios, Kyriakopoulos, Georgios, Argyrakos, Theodore, Pontas, Christos, Papastergiou, Vasilios, Arkadopoulos, Nikolaos, Smyrniotis, Vasilios, Mantzaris, Gerassimos J., and Papanikolaou, Ioannis S.

Published
2021
Full Text
View/download PDF

13. Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece

Author

Gatopoulou, Anthia, Christodoulou, Dimitrios K., Katsanos, Konstantinos H., Bakos, Dimitrios, Mouzas, Ioannis, Tzouvala, Maria, Theodoropoulou, Angeliki, Paspatis, Gregorios, Theocharis, George, Thomopoulos, Konstantinos, Giouleme, Olga, Kourikou, Anastasia, Manolakopoulos, Spilios, Zampeli, Evanthia, Michopoulos, Spyros, Karatzas, Pantelis, Katsaros, Marios, Moschovis, Dimitris, Orfanoudaki, Eleni, Livieratos, Achilleas, Petrikkou, Evangelia, and Mantzaris, Gerassimos J.

Published
2021
Full Text
View/download PDF

19. The Inflammatory Bowel Disease—Disk Tool for Assessing Disability in Inflammatory Bowel Disease Patients: Validation of the Greek Version

Author

Katsoula, Anastasia, primary, Axiaris, Georgios, additional, Mpitouli, Afroditi, additional, Palatianou, Maria, additional, Christidou, Angeliki, additional, Dimitriadis, Nikolaos, additional, Nakos, Andreas, additional, Pastras, Ploutarchos, additional, Kourkoulis, Panagiotis, additional, Karatzas, Pantelis, additional, Moutzoukis, Miltiadis, additional, Zlatinoudis, Charalampos, additional, Philippidis, Athanasios, additional, Kourikou, Anastasia, additional, Kokkotis, Georgios, additional, Gklavas, Antonios, additional, Machaira, Angeliki, additional, Mantaka, Aikaterini, additional, Talimtzi, Persefoni, additional, Anagnostopoulou, Evaggelia, additional, Koutroubakis, Ioannis E., additional, Papaconstantinou, Ioannis, additional, Bamias, Georgios, additional, Manolakopoulos, Spilios, additional, Mathou, Nicoletta, additional, Paraskeva, Konstantina, additional, Protopappas, Andreas, additional, Tsironi, Eftychia, additional, Katsanos, Konstantinos H., additional, Christodoulou, Dimitrios K., additional, Papatheodoridis, Georgios, additional, Michalopoulos, Georgios, additional, Theocharis, Georgios, additional, Triantos, Christos, additional, Pachiadakis, Ioannis, additional, Soufleris, Konstantinos, additional, Viazis, Nikolaos, additional, Mantzaris, Gerassimos J., additional, Tribonias, Georgios, additional, Tzouvala, Maria, additional, Theodoropoulou, Angeliki, additional, Karmiris, Konstantinos, additional, Zampeli, Evanthia, additional, Michopoulos, Spyridon, additional, Haidich, Anna-Bettina, additional, and Giouleme, Olga, additional

Published
2023
Full Text
View/download PDF

20. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study

Author

Fiorino, Gionata, Cortes, Pablo Navarro, Ellul, Pierre, Felice, Carla, Karatzas, Pantelis, Silva, Marco, Lakatos, Peter L., Bossa, Fabrizio, Ungar, Bella, Sebastian, Shaji, Furfaro, Federica, Karmiris, Konstantinos, Katsanos, Konstantinos H., Muscat, Martina, Christodoulou, Dimitrios K., Maconi, Giovanni, Kopylov, Uri, Magro, Fernando, Mantzaris, Gerassimos J., Armuzzi, Alessandro, Boscà-Watts, Marta Maia, Ben-Horin, Shomron, Bonovas, Stefanos, and Danese, Silvio

Published
2016
Full Text
View/download PDF

21. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months – Multicenter European cohort study

Author

Van Assche, Gert, Peyrin-Biroulet, Laurent, Sturm, Andreas, Gisbert, Javier P., Gaya, Daniel R., Bokemeyer, Bern, Mantzaris, Gerassimos J., Armuzzi, Alessandro, Sebastian, Shaji, Lara, Nuria, Lynam, Mark, Rojas-Farreras, Sonia, Fan, Tao, Ding, Qian, Black, Christopher M., and Kachroo, Sumesh

Published
2016
Full Text
View/download PDF

30. Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease

Author

Ellul, Pierre, primary, Schembri, John, additional, Vella Baldacchino, Andrea, additional, Molnár, Tamas, additional, Resal, Tamas, additional, Allocca, Mariangela, additional, Furfaro, Federica, additional, Dal Buono, Arianna, additional, Theodoropoulou, Angeliki, additional, Fragaki, Maria, additional, Tsoukali, Emmanouela, additional, Mantzaris, Gerassimos J, additional, Phillips, Frank M, additional, Radford, Shellie, additional, Moran, Gordon, additional, Gonzalez, Haidee, additional, Sebastian, Shaji, additional, Fousekis, Fotios, additional, Christodoulou, Dimitrios, additional, Snir, Ifat, additional, Lerner, Zlata, additional, Yanai, Henit, additional, Michalopoulos, Georgios, additional, Tua, Julia, additional, Camilleri, Liberato, additional, Papamichael, Kostas, additional, Karmiris, Konstantinos, additional, and Katsanos, Konstantinos, additional

Published
2022
Full Text
View/download PDF

32. S1354 Diabetes as a Risk Factor of Liver Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease

Author

Trikola, Artemis, primary, Papastergiou, Basilios, additional, Mela, Maria, additional, Christidou, Angeliki, additional, Mountaki, Aikaterini, additional, Koustenis, Kanellos, additional, Veretanos, Christos, additional, Karaouzas, Lazaros, additional, Paparizou, Athanasia, additional, Arvanitis, Konstantinos, additional, Archavlis, Emmanouel, additional, Katopodi, Konstantina, additional, Viazis, Nikolaos, additional, and Mantzaris, Gerassimos J., additional

Published
2022
Full Text
View/download PDF

35. Development of an index to define overall disease severity in IBD

Author

Siegel, Corey A, Whitman, Cynthia B, Spiegel, Brennan M R, Feagan, Brian, Sands, Bruce, Loftus, Edward V, Jr, Panaccione, Remo, DʼHaens, Geert, Bernstein, Charles N, Gearry, Richard, Ng, Siew C, Mantzaris, Gerassimos J, Sartor, Balfour, Silverberg, Mark S, Riddell, Robert, Koutroubakis, Ioannis E, OʼMorain, Colm, Lakatos, Peter L, McGovern, Dermot P B, Halfvarson, Jonas, Reinisch, Walter, Rogler, Gerhard, Kruis, Wolfgang, Tysk, Curt, Schreiber, Stefan, Danese, Silvio, Sandborn, William, Griffiths, Anne, Moum, Bjorn, Gasche, Christoph, Pallone, Francesco, Travis, Simon, Panes, Julian, Colombel, Jean-Frederic, Hanauer, Stephen, and Peyrin-Biroulet, Laurent

Published
2018
Full Text
View/download PDF

36. Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

Author

Yanai, Henit, primary, Kagramanova, Anna, additional, Knyazev, Oleg, additional, Sabino, João, additional, Haenen, Shana, additional, Mantzaris, Gerassimos J, additional, Mountaki, Katerina, additional, Armuzzi, Alessandro, additional, Pugliese, Daniela, additional, Furfaro, Federica, additional, Fiorino, Gionata, additional, Drobne, David, additional, Kurent, Tina, additional, Yassin, Sharif, additional, Maharshak, Nitsan, additional, Castiglione, Fabiana, additional, de Sire, Roberto, additional, Nardone, Olga Maria, additional, Farkas, Klaudia, additional, Molnar, Tamas, additional, Krznaric, Zeljko, additional, Brinar, Marko, additional, Chashkova, Elena, additional, Livne Margolin, Moran, additional, Kopylov, Uri, additional, Bezzio, Cristina, additional, Bar-Gil Shitrit, Ariella, additional, Lukas, Milan, additional, Chaparro, María, additional, Truyens, Marie, additional, Nancey, Stéphane, additional, Lobaton, Triana, additional, Gisbert, Javier P, additional, Saibeni, Simone, additional, Bacsúr, Péter, additional, Bossuyt, Peter, additional, Schulberg, Julien, additional, Hoentjen, Frank, additional, Viganò, Chiara, additional, Palermo, Andrea, additional, Torres, Joana, additional, Revés, Joana, additional, Karmiris, Konstantinos, additional, Velegraki, Magdalini, additional, Savarino, Edoardo, additional, Markopoulos, Panagiotis, additional, Tsironi, Eftychia, additional, Ellul, Pierre, additional, Calviño Suárez, Cristina, additional, Weisshof, Roni, additional, Ben-Hur, Dana, additional, Naftali, Timna, additional, Eriksson, Carl, additional, Koutroubakis, Ioannis E, additional, Foteinogiannopoulou, Kalliopi, additional, Limdi, Jimmy K, additional, Liu, Eleanor, additional, Surís, Gerard, additional, Calabrese, Emma, additional, Zorzi, Francesca, additional, Filip, Rafał, additional, Ribaldone, Davide Giuseppe, additional, Snir, Yifat, additional, Goren, Idan, additional, Banai-Eran, Hagar, additional, Broytman, Yelena, additional, Amir Barak, Hadar, additional, Avni-Biron, Irit, additional, Ollech, Jacob E, additional, Dotan, Iris, additional, and Aharoni Golan, Maya, additional

Published
2022
Full Text
View/download PDF

38. Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series

Author

MS MDL 1, Infection & Immunity, Albshesh, Ahmad, Eder, Piotr, Ribaldone, Davide Giuseppe, Oldenburg, Bas, de Boer, Nanne K, Mantzaris, Gerassimos J, Savarino, Edoardo Vincenzo, Dragoni, Gabriele, Weisshof, Roni, Truyens, Marie, Festa, Stefano, Maillard, Michel H, Capirchio, Lena, Filip, Rafal, Theodoraki, Eirini, Kopylov, Uri, MS MDL 1, Infection & Immunity, Albshesh, Ahmad, Eder, Piotr, Ribaldone, Davide Giuseppe, Oldenburg, Bas, de Boer, Nanne K, Mantzaris, Gerassimos J, Savarino, Edoardo Vincenzo, Dragoni, Gabriele, Weisshof, Roni, Truyens, Marie, Festa, Stefano, Maillard, Michel H, Capirchio, Lena, Filip, Rafal, Theodoraki, Eirini, and Kopylov, Uri

Published
2022

40. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Author

Gomollón, Fernando, Dignass, Axel, Annese, Vito, Tilg, Herbert, Van Assche, Gert, Lindsay, James O., Peyrin-Biroulet, Laurent, Cullen, Garret J., Daperno, Marco, Kucharzik, Torsten, Rieder, Florian, Almer, Sven, Armuzzi, Alessandro, Harbord, Marcus, Langhorst, Jost, Sans, Miquel, Chowers, Yehuda, Fiorino, Gionata, Juillerat, Pascal, Mantzaris, Gerassimos J., Rizzello, Fernando, Vavricka, Stephan, and Gionchetti, Paolo

Published
2017
Full Text
View/download PDF

41. Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease.

Author

Ellul, Pierre, Schembri, John, Baldacchino, Andrea Vella, Molnár, Tamas, Resal, Tamas, Allocca, Mariangela, Furfaro, Federica, Buono, Arianna Dal, Theodoropoulou, Angeliki, Fragaki, Maria, Tsoukali, Emmanouela, Mantzaris, Gerassimos J, Phillips, Frank M, Radford, Shellie, Moran, Gordon, Gonzalez, Haidee, Sebastian, Shaji, Fousekis, Fotios, Christodoulou, Dimitrios, and Snir, Ifat

Abstract

Background and Aims Post-inflammatory polyps [PIPs] are considered as indicators of previous episodes of severe inflammation and mucosal ulceration. Inflammatory bowel disease [IBD], namely Crohn's disease [CD] and ulcerative colitis [UC], exhibit a perpetuating, relapsing and remitting pattern, and PIPs are a frequent sequela of chronicity. The aim of this study was to determine whether a high PIP burden is associated with a more severe disease course in patients with IBD. Methods This was a multinational, multicentre, retrospective study. IBD patients previously diagnosed with PIPs were retrieved from the endoscopic database of each centre. PIP burden was evaluated and associated with demographic and clinical data as well as factors indicating a more unfavourable disease course. Results A total of 504 IBD patients with PIPs were recruited [male: 61.9%]. The mean age at IBD diagnosis was 36.9 [±16.8] years. Most patients [74.8%] were diagnosed with UC. A high PIP burden was present in 53.4% of patients. On multivariable Cox regression analysis, a high PIP burden was independently associated with treatment escalation (hazard ratio [HR] 1.35, 95% confidence interval [CI] 1.04–1.75; p  = 0.024), hospitalization [HR 1.90; 95% CI 1.24–2.90; p  = 0.003], need for surgery [HR 2.28; 95% CI 1.17–4.44, p  = 0.02] and younger age at diagnosis [HR 0.99, 95% CI 0.98–0.99; p  = 0.003]. Conclusion PIP burden was associated with a more severe outcome. Future prospective studies should focus on the characterization of PIP burden as to further risk stratify this patient cohort. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Author

Orfanoudaki, Eleni, primary, Zacharopoulou, Eirini, additional, Kitsou, Vassiliki, additional, Karmiris, Konstantinos, additional, Theodoropoulou, Angeliki, additional, Mantzaris, Gerassimos J., additional, Tzouvala, Maria, additional, Viazis, Nikos, additional, Michopoulos, Spyridon, additional, Zampeli, Evanthia, additional, Michalopoulos, Georgios, additional, Karatzas, Pantelis, additional, Liatsos, Christos, additional, Bamias, Giorgos, additional, and Koutroubakis, Ioannis E., additional

Published
2022
Full Text
View/download PDF

44. Tu1549: IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARSCOV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY

Author

Revés, Joana, primary, Abreu, Bárbara S., additional, Chaparro, María, additional, Gisbert, Javier P., additional, Allocca, Mariangela, additional, Fiorino, Gionata, additional, Barberio, Brigida, additional, Zingone, Fabiana, additional, Pisani, Anthea, additional, Cassar, David, additional, Michalopoulos, Georgios, additional, Mantzaris, Gerassimos J., additional, Mountaki, Katerina, additional, Koutroubakis, Ioannis E., additional, Karmiris, Konstantinos, additional, Katsanos, Konstantinos, additional, Duricova, Dana, additional, Burisch, Johan M., additional, Madsen, Gorm Roager, additional, Maaser, Christian, additional, Arebi, Naila, additional, Orfanoudaki, Eleni, additional, Milivojevic, Vladimir, additional, Buisson, Anthony, additional, Avedano, Luisa, additional, Leone, Salvatore, additional, Torres, Joana, additional, and Ellul, Pierre, additional

Published
2022
Full Text
View/download PDF

45. Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY

Author

Zacharopoulou, Eirini, primary, Orfanoudaki, Eleni, additional, Kitsou, Vassiliki, additional, Tzouvala, Maria, additional, Tribonias, George, additional, Mantzaris, Gerassimos J., additional, Viazis, Nikos, additional, Christidou, Angeliki, additional, Georgiadi, Tereza, additional, Karmiris, Konstantinos, additional, Theodoropoulou, Angeliki, additional, Tsafaridou, Maria, additional, Michopoulos, Spyridon, additional, Zampeli, Evanthia, additional, Papathanasiou, Evgenia, additional, Michalopoulos, Georgios, additional, Tigkas, Stefanos, additional, Karatzas, Pantelis, additional, Laoudi, Effrosyni, additional, Liatsos, Christos, additional, Kyriakos, Nikolaos, additional, Mylonas, Iordanis, additional, Theocharis, Georgios J., additional, Kafentzi, Theodora, additional, Koutroubakis, Ioannis E., additional, and Bamias, Giorgos, additional

Published
2022
Full Text
View/download PDF

46. Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry

Author

Zacharopoulou, Eirini, primary, Orfanoudaki, Eleni, additional, Tzouvala, Maria, additional, Tribonias, George, additional, Kokkotis, Georgios, additional, Kitsou, Vassiliki, additional, Almpani, Foteini, additional, Christidou, Aggeliki, additional, Viazis, Nikolaos, additional, Mantzaris, Gerassimos J, additional, Tsafaridou, Maria, additional, Karmiris, Konstantinos, additional, Theodoropoulou, Angeliki, additional, Papathanasiou, Evgenia, additional, Zampeli, Evanthia, additional, Michopoulos, Spyridon, additional, Tigkas, Stefanos, additional, Michalopoulos, Georgios, additional, Laoudi, Efrossini, additional, Karatzas, Pantelis, additional, Mylonas, Iordanis, additional, Kyriakos, Nikolaos, additional, Liatsos, Christos, additional, Kafetzi, Theodora, additional, Theocharis, Georgios, additional, Taka, Styliani, additional, Panagiotopoulou, Konstantina, additional, Koutroubakis, Ioannis E, additional, and Bamias, Giorgos, additional

Published
2022
Full Text
View/download PDF

47. Poor performance of predictive equations to estimate resting energy expenditure in patients with Crohn’s disease

Author

Karachaliou, Alexandra, primary, Anastasiou, Costas, additional, Bletsa, Maria, additional, Mantzaris, Gerassimos J., additional, Archavlis, Emmanuel, additional, Karampekos, George, additional, Tzouvala, Maria, additional, Zacharopoulou, Eirini, additional, Veimou, Chrysoula, additional, Bamias, Giorgos, additional, and Kontogianni, Meropi, additional

Published
2022
Full Text
View/download PDF

48. Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease

Author

Orfanoudaki, Eleni Zacharopoulou, Eirini Kitsou, Vassiliki and Karmiris, Konstantinos Theodoropoulou, Angeliki Mantzaris, Gerassimos J. Tzouvala, Maria Michopoulos, Spyridon Zampeli, Evanthia Michalopoulos, Georgios Karatzas, Pantelis Viazis, Nikos Liatsos, Christos Bamias, Giorgos Koutroubakis, Ioannis E. Hellen Grp Study IBD

Abstract

Since inflammatory bowel disease (IBD) patients were excluded from vaccine authorization studies, limited knowledge exists regarding perceptions and unfavorable effects of COVID-19 vaccination in this group. We aimed to investigate the real-world use and adverse events (AEs) of COVID-19 vaccines in Greek IBD patients. Fully vaccinated IBD patients followed in Greek centers were invited to participate. All patients filled out an anonymous online survey concerning the vaccination program, which included information regarding demographics, clinical characteristics, treatment, vaccination perceptions and potential AEs. Overall, 1007 IBD patients were included. Vaccine hesitancy was reported by 49%. Total AEs to vaccination were reported by 81% after dose 1 (D1) and 76% after dose 2 (D2), including isolated injection site reactions (36% and 24% respectively). Systemic AEs were more common after D2 (51%, D2 vs. 44%, D1, p < 0.0001). Very few patients reported new onset abdominal symptoms (abdominal pain 4% (D1), 6% (D2) and diarrhea 5% (D1), 7% (D2)). There were no serious AEs leading to emergency room visit or hospitalization. In multivariate analysis, AEs occurrence was positively associated with young age and female gender (p < 0.0005 for both doses), whereas inactive disease was negatively associated with AE in D1 (p = 0.044). SARS-CoV-2 vaccination in Greek IBD patients demonstrated a favorable and reassuring safety profile.

Published
2022

49. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates

Author

Viazis, Nikos, primary, Argyriou, Konstantinos, additional, Kotzampassi, Katerina, additional, Christodoulou, Dimitrios K., additional, Apostolopoulos, Periklis, additional, Georgopoulos, Sotirios D., additional, Liatsos, Christos, additional, Giouleme, Olga, additional, Koustenis, Kanellos, additional, Veretanos, Christos, additional, Stogiannou, Dimitris, additional, Moutzoukis, Miltiadis, additional, Poutakidis, Charalambos, additional, Mylonas, Ioannis Ioardanis, additional, Tseti, Ioulia, additional, and Mantzaris, Gerassimos J., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results